Bionure is a clinical-stage biotech company developing therapies for the treatment of neurodegenerative diseases for which no treatment options are nowadays available. Bionure has outsourced the development of part of its portfolio to an investee company and is managing the rest of its portfolio internally. Our lead candidate BN201 is a small molecule, new chemical entity, first-in-class drug that has been shown to promote neuroprotection and remyelination in several animal models of damage. BN201 has been granted orphan designation for acute optic neuritis in Europe and the US and has been licensed to Oculis. The product is now in clinical Phase 2 in France. With patients in mind, we have built an extraordinary, committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of thousands of people.